← Eichor
Study identifier: NCT07172646 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study of SRSD216 in Patients With Elevated Lipoprotein (a)

Condition: Hyperlipoproteinemia (a)  ·  Sponsor: Sirius Therapeutics Co., Ltd.

PhasePhase 1/Phase 2
Planned participants84
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersYes

About this study

This is a two-part study, intended to investigate the safety, tolerability, characteristics of PK and PD of single SC dose of SRSD216 and to identify a dose range for further studies in subjects with elevated Lp(a) level with or without ASCVD history.

This description comes directly from the study's public registry record.

Talk to the study team

Medical Director  ·  +86 21 61207756  ·  medical@siriusrna.com

Always discuss trial participation with your own doctor first.

Locations (1)

Site 01Beijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07172646